| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/03/2004 | US20040105855 Compries immunoglobulin which binds tumor necrosis factor receptor and functions as antitumor agent in the treatment of cancer |
| 06/03/2004 | US20040105854 monoclonal or polyclonal antibodies with histidine polypeptides for immunization |
| 06/03/2004 | CA2506696A1 Method for the prevention of malaria |
| 06/03/2004 | CA2506684A1 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2 |
| 06/03/2004 | CA2506230A1 Anti-angiogenic uses of il-6 antagonists |
| 06/03/2004 | CA2505994A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 06/03/2004 | CA2505601A1 Complement receptor 2 targeted complement modulators |
| 06/03/2004 | CA2505167A1 Gastrin compositions and formulations, and methods of use and preparation |
| 06/03/2004 | CA2504930A1 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 06/03/2004 | CA2502668A1 Fully human antibody fab fragments with human interferon-gamma neutralizing activity |
| 06/03/2004 | CA2483870A1 Interacting site for gp41 on gp120 of hiv-1 |
| 06/02/2004 | EP1424387A1 Method of extended culture for antigen-specific cytotoxic t lymphocytes |
| 06/02/2004 | EP1424066A1 Dry compositions comprising hydrophobic stabilisers |
| 06/02/2004 | EP1423708A1 Compositions and methods for aa4rp assay |
| 06/02/2004 | EP1423701A2 Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| 06/02/2004 | EP1423697A2 Secreted proteins |
| 06/02/2004 | EP1423693A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy |
| 06/02/2004 | EP1423525A1 Recombinant mva capable of expressing structural hcv antigens |
| 06/02/2004 | EP1423510A2 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| 06/02/2004 | EP1423432A2 Interleukin-1 beta antibodies |
| 06/02/2004 | EP1423431A2 Antibodies to vla-1 |
| 06/02/2004 | EP1423430A1 A method of producing antibodies ex-vivo |
| 06/02/2004 | EP1423429A2 Antibodies against caspase-8, their preparation and use |
| 06/02/2004 | EP1423428A2 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 06/02/2004 | EP1423425A2 Receptor, the use thereof, and mouse antibodies |
| 06/02/2004 | EP1423422A2 A caspase- 8 binding protein, its preparation and use |
| 06/02/2004 | EP1423421A2 Isolation and purification of p. falciparum merozoite protein-1 42 vaccine |
| 06/02/2004 | EP1423419A2 Hybrid and tandem expression of neisserial proteins |
| 06/02/2004 | EP1423418A1 Mutated env gene, mutated env glycoprotein and the use thereof |
| 06/02/2004 | EP1423417A2 Peptides mimicking a cryptic epitope of gp41 of hiv-1 and antibodies directed against them |
| 06/02/2004 | EP1423415A2 Intracellular signaling molecules |
| 06/02/2004 | EP1423405A2 Plasmodium falciparum ama-1 protein and uses thereof |
| 06/02/2004 | EP1423169A2 Potentiator composition comprising a terpene for enhancing the therapeutical effect of antitumoral agents in the treatment of cancer |
| 06/02/2004 | EP1423144A2 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
| 06/02/2004 | EP1423142A1 Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins |
| 06/02/2004 | EP1423141A1 Vaccine |
| 06/02/2004 | EP1423138A2 Use of il-18 inhibitors in hypersensitivity disorders |
| 06/02/2004 | EP1423135A2 Methods for inhibiting angiogenesis |
| 06/02/2004 | EP1423129A1 Therapeutic process for p. aeruginosa infections using macrolide antibiotics |
| 06/02/2004 | EP1423128A2 Methods for the treatment of chronic pain anc compositions therefor |
| 06/02/2004 | EP1423012A2 Isolation and mobilization of stem cells expressing vegfr-1 |
| 06/02/2004 | EP0807178B1 Mycobacterial proteins, microorganisms producing same and uses of said proteins in vaccines and for detecting tuberculosis |
| 06/02/2004 | EP0792279B1 Antibiotic cryptdin peptides and methods of their use |
| 06/02/2004 | EP0729513B1 Analog of haemophilus hin47 with reduced protease activity |
| 06/02/2004 | CN1501812A Antithrombotic agents |
| 06/02/2004 | CN1501811A Compositions for stimulating cytokine secretion and inducing an immune response |
| 06/02/2004 | CN1501810A Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| 06/02/2004 | CN1500866A Large brill rhabdo virus toxic strain and its preparation method and application |
| 06/02/2004 | CN1500865A Lefteye flounder lymph tumour virus toxic strain, its preparation method and application |
| 06/02/2004 | CN1500864A Mandarin fish rhabdo virus toxic strain, its preparation method and application |
| 06/02/2004 | CN1151843C Novel anti-tumor medicine and its screening method and use |
| 06/02/2004 | CN1151842C Stable isotonic lyophilized protein formulation |
| 06/02/2004 | CN1151799C Bacterial membrane fractions with adjuvant effect |
| 06/01/2004 | US6743908 For use in cancer diagnosis and therapy |
| 06/01/2004 | US6743900 Viral protein antigen (especially influenza virus hemagglutinin), proteosome preparation and detergent; removing detergent by diafiltration or ultrafiltration |
| 06/01/2004 | US6743896 Protien for use in the treatment of infection and tumors |
| 06/01/2004 | US6743625 Death domain containing receptor 5 |
| 06/01/2004 | US6743611 For encoding clover yellow vein virus nuclear inclusion-a proteins; proteases; aminopeptidases |
| 06/01/2004 | US6743444 Method of making microencapsulated DNA for vaccination and gene therapy |
| 06/01/2004 | US6743431 Capsular polysaccharide adhesin antigen, preparation, purification and use |
| 06/01/2004 | US6743430 Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose |
| 06/01/2004 | US6743427 Prevention and treatment of amyloidogenic disease |
| 06/01/2004 | CA2285058C Coincidence detection method, products and apparatus |
| 06/01/2004 | CA2034034C Process for the production of antibodies |
| 05/27/2004 | WO2004044591A2 Use of nuclear hormone receptors to identify meiosis regulating compounds |
| 05/27/2004 | WO2004044235A1 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1) |
| 05/27/2004 | WO2004044220A2 Flaviviris fusion inhibitors |
| 05/27/2004 | WO2004044164A2 Method for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | WO2004044163A2 Methods for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | WO2004044155A2 MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| 05/27/2004 | WO2004044149A2 Method for suppressing immune system response to transplanted tissue or cells |
| 05/27/2004 | WO2004044000A2 Compounds and methods for modulating functions of classical cadherins |
| 05/27/2004 | WO2004043988A2 Ptprk immunogenic peptide |
| 05/27/2004 | WO2004043490A1 Smallpox vaccine regimen |
| 05/27/2004 | WO2004043489A1 Method of obtaining conjugate vaccines and vaccine compositions containing same |
| 05/27/2004 | WO2004043488A1 Malaria vaccine |
| 05/27/2004 | WO2004043428A2 Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| 05/27/2004 | WO2004043405A2 Polysaccharide vaccine for staphylococcal infections |
| 05/27/2004 | WO2004043399A2 Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| 05/27/2004 | WO2004043376A2 Compositions and methods for treating or preventing pneumococcal infection |
| 05/27/2004 | WO2004043353A2 Compositions and methods for treating acute myeloid leukemia |
| 05/27/2004 | WO2004043344A2 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 05/27/2004 | WO2004043340A2 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 05/27/2004 | WO2004043338A2 Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
| 05/27/2004 | WO2004043332A2 Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
| 05/27/2004 | WO2004043287A2 Novel compositions that enhance production performance in avians |
| 05/27/2004 | WO2004043286A2 Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen |
| 05/27/2004 | WO2004043233A2 Assay for autoantibodies to folate receptors |
| 05/27/2004 | WO2004043232A2 Methods for identifying risk of melanoma and treatments thereof |
| 05/27/2004 | WO2004043141A2 Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians |
| 05/27/2004 | WO2004028259A3 A method for stabilizing bioactive molecules |
| 05/27/2004 | WO2004008147A3 Diagnosis and prevention of cancer cell invasion |
| 05/27/2004 | WO2004006855A3 Rhodococcus equi mutants and vaccines comprising same |
| 05/27/2004 | WO2004001655A8 Methods of treating and preventing colitis involving il-13 and nk-t cells |
| 05/27/2004 | WO2003081258A3 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs) |
| 05/27/2004 | WO2003061589A3 Methods for treating diseases or conditions with peptide constructs |
| 05/27/2004 | WO2003044183A8 Interleukin-2 gene transferred lymphokine activated killer cells |
| 05/27/2004 | WO2003034977A3 Combination therapy for treating disease |
| 05/27/2004 | WO2003015705A3 In situ immunization |
| 05/27/2004 | WO2003008541A8 Extracellular junctional adhesion molecules |